<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867617</url>
  </required_header>
  <id_info>
    <org_study_id>Trex001</org_study_id>
    <nct_id>NCT03867617</nct_id>
  </id_info>
  <brief_title>Cell Therapy for Immunomodulation in Kidney Transplantation</brief_title>
  <official_title>A Prospective Controlled Trial to Evaluate Safety and Efficacy of in Vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-mismatched Living Donor Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Wekerle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates treatment with recipient regulatory T cells and donor bone marrow
      together with tocilizumab for immunomodulation in living donor kidney transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured as GVHD (graft-versus-host disease), impaired graft function or patient death</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of composite safety endpoint by 12 months post-transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chimerism</measure>
    <time_frame>1 month</time_frame>
    <description>Total leukocyte donor chimerism in blood.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Regulatory T cells</intervention_name>
    <description>Single infusion of expanded regulatory T cells.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Treatment during first month post-transplant.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone marrow</intervention_name>
    <description>Infusion of donor bone marrow cells.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney transplant</intervention_name>
    <description>Living donor kidney transplantation.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunosuppressive drug therapy</intervention_name>
    <description>Immunosuppressive drug therapy.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has provided written informed consent.

          -  Patient is 18 years or older.

          -  Patient is a planned recipient of a living donor kidney transplant.

          -  Patient is a planned recipient of an ABO blood group-compatible kidney graft.

          -  Patient is a planned recipient of a kidney graft from a donor that is not HLA (human
             leukocyte antigen)-identical.

          -  Patient is negative for DSA (donor-specific antibodies).

          -  WOCBP (women of child-bearing potential) must have a negative pregnancy test at
             inclusion.

          -  WOCBP must be using an adequate method of contraception to avoid pregnancy throughout
             the study and for up to 12 weeks after the study in such a manner that the risk of
             pregnancy is minimized.

        Exclusion Criteria:

          -  Patient is EBV (epstein barr virus)-negative on serology.

          -  Patient is HIV-positive or suffering from chronic viral hepatitis.

          -  Patient is CMV (cytomegalo virus)-negative and receiving a kidney from a CMV-positive
             donor.

          -  Positive T-cell lymphocytotoxic cross match.

          -  Patient with prior kidney transplant or non-renal solid organ transplant.

          -  Patient has a known contraindication to any of the protocol-specified treatments.

          -  Patient had been diagnosed with a malignancy within 5 years prior to study entry,
             excluding non-metastatic basal or squamous cell carcinoma of the skin.

          -  Female patients who are breast-feeding.

          -  Female patients with a positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Wekerle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Wekerle, MD</last_name>
    <phone>+43-1-40400</phone>
    <phone_ext>39380</phone_ext>
    <email>Thomas.Wekerle@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna/Vienna General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wekerle, MD</last_name>
      <phone>+43-1-40400</phone>
      <phone_ext>39380</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Thomas Wekerle</investigator_full_name>
    <investigator_title>Professor of Transplantation Immunology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

